Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Bone pain palliation with Strontium-89 in cancer patients with bone metastases
Autore:
Giammarile, F; Mognetti, T; Resche, I;
Indirizzi:
Ctr Leon Berard, Nucl Med Serv, F-69373 Lyon 08, France Ctr Leon Berard Lyon France 08 d, Nucl Med Serv, F-69373 Lyon 08, France CHU Edouard Herriot, Lyon, France CHU Edouard Herriot Lyon FranceCHU Edouard Herriot, Lyon, France Ctr Rene Gauducheau, F-44035 Nantes, France Ctr Rene Gauducheau Nantes France F-44035 ucheau, F-44035 Nantes, France
Titolo Testata:
QUARTERLY JOURNAL OF NUCLEAR MEDICINE
fascicolo: 1, volume: 45, anno: 2001,
pagine: 78 - 83
SICI:
1125-0135(200103)45:1<78:BPPWSI>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
SR-89 THERAPY; PROSTATIC-CARCINOMA; OSSEOUS METASTASES; CHLORIDE; RADIOTHERAPY; DOSIMETRY; LEUKEMIA; KINETICS;
Keywords:
strontium radioisotopes, therapeutic use; bone neoplasms, secondary; bone neoplasms, radiotherapy; pain, therapy; radiopharmaceuticals;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Giammarile, F Ctr Leon Berard, Nucl Med Serv, 28 Rue Laennec, F-69373 Lyon08, France Ctr Leon Berard 28 Rue Laennec Lyon France 08 on 08, France
Citazione:
F. Giammarile et al., "Bone pain palliation with Strontium-89 in cancer patients with bone metastases", Q J NUCL M, 45(1), 2001, pp. 78-83

Abstract

Strontium-89 is a pure beta -emitting radioisotope, a chemical analogue ofcalcium, and it is therefore avidly concentrated by areas of high osteoblastic activity. Selective uptake and prolonged retention at sites of increased bone mineral turnover provide precise bone lesions targeting. Sr-89 chloride (commercialised as Metastron((R))) is typically administered in a single 150 MBq parenteral dose. Its radioactive emission poses very Little radioprotection concerns. Overall, studies show pain relief in up to 80% of patients, of which 10 to 40% became effectively pain free. The mean duration of palliation was 34 months. The mechanism of pain relief is controversial; it is probably, but not only, related to the absorbed dose in the tumour and bone. There is no clear dose-response relationship. The only reported toxicity is temporary myelosuppression. WBC and platelets should be monitored at least on a weekly basis until they return to baseline. It seems that only patients with a reasonably good general condition stand to benefit from this treatment. In conclusion, systemic radionuclide therapy using Sr-89 represents a feasible, safe, effective, well tolerated and cost-effective palliative treatment in;patients with refractory bone pain.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 12:31:37